Metformin in the treatment of non-alcoholic fatty liver disease: Safety, efficacy and mechanism

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 4, 2014, Pages 343-349

  Rouabhia, Samir ^a   Milic, Natasa ^b   Abenavoli, Ludovico ^c  

^a University Hospital Center Touhami Benflis Algeria   (Algeria)

^b UNIVERSITY OF NOVI SAD   (Serbia)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

insulin resistance; metformin; non alcoholic fatty liver disease; non alcoholic steatohepatitis; steatosis

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; METFORMIN; PIOGLITAZONE; PLACEBO; PROBIOTIC AGENT; ROSIGLITAZONE; SILYMARIN; ANTIDIABETIC AGENT;

ARTICLE; BLOATING; CALORIC RESTRICTION; COMBINATION CHEMOTHERAPY; DIARRHEA; DIET THERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METALLIC TASTE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; DISEASE COURSE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84898957586     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.894880     Document Type: Article

References (52)

1. Day CP. Clinical spectrum and therapy of non-alcoholic steatohepatitis. Dig Dis 2012; 30(Suppl 1):69-73
2. Alwis NMW, Day CP. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48:S104-12
3. Angulo P. Medical progress non-alcoholic fatty liver disease. N Engl J Med 2002;346: 1221-31 (Pubitemid 34984585)
4. Abenavoli L, Bellentani S. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? Expert Rev Gastroenterol Hepatol 2013;7(8):677-9
5. Younossi ZM, Reyes MJ, Mishra A, et al. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39(1):3-14
6. Sookoian S, Pirola CJ. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One 2013;8(3): e58895
7. Bugianesi E, Zannoni C, Vanni E, et al. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2004;36(3):165-73 (Pubitemid 41130632)
8. Medina J, Ferna'ndez-Salazar LI, Garci'a-Buey L, et al. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004;27(8): 2057-66 (Pubitemid 38989257)
9. Cicero AF, Tartagni E, Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci 2012;8(5):907-17
10. Angelico F, Burattin M, Alessandri C, et al. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007(1):CD005166
11. Comar KM, Sterling RK. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006; 23(2):207-15 (Pubitemid 43382029)
12. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003
13. Kita Y, Takamura T, Misu H, et al. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One 2012;7:e43056
14. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4 (Pubitemid 32900577)
15. Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009;29(2):172-82
16. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20(1):23-8 (Pubitemid 38938715)
17. Duseja A, Das A, Dhiman RK, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007;6(4):222-6
18. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44 (Pubitemid 38387180)
19. Garinis GA, Fruci B, Mazza A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes 2010;34(8):1255-64
20. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009;46(2): 113-18
21. Haukeland JW, Konopski Z, Eggesbø HB, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009;44(7):853-60
22. Shields WW, Thompson KE, Grice GA, et al. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): a Pilot Trial. Therap Adv Gastroenterol 2009;2(3):157-63
23. Shargorodsky M, Omelchenko E, Matas Z, et al. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovasc Diabetol 2012;11:61
24. Sofer E, Boaz M, Matas Z, et al. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 2011;60(9):1278-84
25. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100(5):1082-90 (Pubitemid 40769045)
26. Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22(1):18-23
27. Hajiaghamohammadi AA, Ziaee A, Oveisi S, et al. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat Mon 2012;12(8):e6099
28. de Oliveira CP, Stefano JT, de Siqueira ER, et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 2008;38(2): 159-65
29. Shavakhi A, Minakari M, Firouzian H, et al. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: a Double Blind Randomized Clinical Trial. Int J Prev Med 2013;4(5): 531-7
30. Bosi E. Metformin - the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 2009;11(Suppl 2): 3-8
31. UK Prospective Diabetes study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
32. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21(10):1659-63 (Pubitemid 28449803)
33. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013;12(2): 153-75
34. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013;5(1):6
35. Urso R, Visco-Comandini U. Metformin in non-alcoholic steatohepatitis. Lancet 2002; 359(9303):355-6
36. Barbero-Becerra VJ, Santiago-Hernandez JJ, Villegas-Lopez FA, et al. Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease. Curr Med Chem 2012;19(18): 2918-23
37. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333(9):550-4
38. Bugianesi E, Marzocchi R, Villanova N, et al. Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol 2004;18(6):1105-16 (Pubitemid 39517695)
39. Mazza A, Fruci B, Garinis GA, et al. The role of metformin in the management of NAFLD. Exp Diabetes Res 2012;2012:716404
40. Liu F, Wang C, Zhang L, et al. Metformin prevents hepatic steatosis by regulating the expression of adipose differentiation-related protein. Int J Mol Med 2014;33(1):51-8
41. Huang Y, Fu JF, Shi HB, Liu LR. Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes. Zhonghua Er Ke Za Zhi 2011;49:139-45
42. Nakajima K. Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. Int J Hepatol 2012;2012:950693
43. Fruci B, Giuliano S, Mazza A, et al. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci 2013;14(11): 22933-66
44. Shyangdan D, Clar C, Ghouri N, et al. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess 2011;15(38): 1-110
45. Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55(4):885-904
46. Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28(2):200-8
47. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55(6):2005-23
48. Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol 2013;28(Suppl 4):64-70
49. Takei Y. Treatment of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2013; 28(Suppl 4):79-80
50. Miyake T, Kumagi T, Furukawa S, et al. Non-alcoholic fatty liver disease: factors associated with its presence and onset. J Gastroenterol Hepatol 2013;28(Suppl 4): 71-8
51. Fogari R, Maffioli P, Mugellini A, et al. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol 2013;24(2): 164-71
52. Maffioli P, Fogari ED, Angelo A, et al. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. Eur J Gastroenterol Hepatol 2013;25(9):1113-22